AndreaBozzo/ceres-open-data-index huggingface dataset:
Drug Abuse Warning Network (DAWN-2011)

<p>The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.<br />
DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.<br />
The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year.  Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.</p>
Compound 528130: 3-Methyl-5-(2-methylbutyl)-2-(methylthio)pyrazine

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-5-(2-methylbutyl)-2-methylsulfanylpyrazine. Molecular Formula: C11H18N2S. Molecular Weight: 210.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Separate urinary bladder and prostate neurons in the central nervous system of the rat: simultaneous labeling with two immunohistochemically distinguishable pseudorabies viruses

Background
          This work examines the central nervous system distribution of virus-labeled neurons from the rat urinary bladder and the prostate simultaneously within the same tissue sections. Two immunohistochemically distinct pseudorabies virus strains were simultaneously injected into male Sprague Dawley rats (~280 gm). One virus was injected into the bladder and the other into the prostate. After incubation intervals of 2.25, 2.5, 2.75, 3 and 4 days, sections from the spinal cord and brain were processed immunohistochemically to detect cells, within a single section, which were labeled separately by each virus or were labeled by both viruses.
        
        
          Results
          Each strain of virus labeled a separate population of neurons and some neurons were labeled by both strains. The majority of neurons labeled by virus from the urinary bladder were found in the L6-S1 spinal cord segments within the dorsal gray commissure, the intermediolateral area and the superficial dorsal horn. Neurons labeled by virus from the prostate were mainly found in the L1-L2 spinal cord segments in the dorsal gray commissure and the intermediolateral areas. Double-labeled interneurons in L1-L2 were mainly located in the intermediolateral area. In L6-S1 they were divided between the dorsal gray commissure and the intermediolateral area.
        
        
          Conclusions
          Spinal neurons innervating the bladder are clearly separate and different from those innervating the prostate. This difference also persists in the brain. In disagreement with previous reports, no direct anatomical evidence of parasympathetic innervation of the prostate was observed.
Do pediatric intensivists and radiologists concur on the interpretation of chest radiographs?

Background:
          Therapeutic decisions in the pediatric intensive care unit are made by pediatric intensivists (PI) based on their interpretation of chest radiographs before the formal interpretation by a pediatric radiologist (PR). This study was designed to determine the adequacy of chest radiograph interpretations by pediatric intensivists and the effects on patient care. The PI recorded their chest radiograph interpretations, documenting support devices and thoracic abnormalities. Concordance and discordance were determined by the pediatric pulmonologist who was not involved in the care of the patient by comparing the interpretations of the PI and PR. Clinically significant discordance was defined as interpretations by the radiologist that differed to those from the PI that may have required therapeutic intervention.
        
        
          Results:
          The evaluation of 291 chest radiographs demonstrated an overall concordance rate of 82.5% (240 out of 291; P < 0.05). There was no significant difference in the ability of critical care medicine physicians to identify atelectasis, infiltrates, pleural effusions, or airleaks (P > 0.05). Support devices were correctly identified in 100% of the cases. Discordant interpretations included 20 that were clinically significant, 17 insignificant findings and 14 films over-interpreted by the PI. A chart review of the patients with discordant findings revealed only one finding that required an alteration in therapy.
        
        
          Conclusions:
          These findings demonstrate significant agreement between the interpretation of chest radiographs by PI and PR in selected clinical situations. These data support the current practice of the PI making therapeutic decisions based on their interpretations of chest radiographs.
FY 2004 Children's Bureau Competitive Cooperative Agreements and Discretionary Grant Awards

This document provides a list of Children's Bureau discretionary grants and cooperative agreements awarded in fiscal year 2004:

Seven National Child Welfare Resource Centers (CFDA #93.556) - Cooperative Agreements - $6,699,915 per year for 5 years

National Resource Center for Community-Based Grants for the Prevention of Child Abuse and Neglect (CFDA #93.590) - Cooperative Agreement - $1,075,000 per year for 5 years

Infant Adoption Awareness Training Program (CFDA #93.254) - Cooperative Agreement - 
total awarded $9,812,761 per year for 2 years

Child Welfare Training—MSW (CFDA #93.648) - up to $100,000 per year for 4 years

Child Welfare Training—Hispanic (CFDA #93.648) up to $200,000 per year for 3 years

Child Welfare Training - BSW (CFDA #93.648) - up to $100,000 per year for 5 years

Demonstration Projects in Post-Adoption Services and Marriage Education (CFDA #93.652) - up to $300,000 per year for 5 years

Field Initiated Service Demonstration Projects in the Adoption Field (CFDA #93.652) - up to $400,000 per year for 4 years

Recreational Services for Children Affected by HIV/AIDS (CFDA #93.551) - up to $100,000 per year for 4 years

Previous Abandoned Infant Comprehensive Service Demonstration Projects (CFDA #93.551) - up to $450,000 per year for 4 years

New Start Local Comprehensive Support Services Projects (CFDA #93.551)
up to $450,000 per year for 4 years

Family Support Services for Grandparents and Other Relatives Providing Caregiving for Children of Substance Abusing and/or HIV-Positive Women (CFDA #93.551) - up to $100,000 per year for 4 years

Metadata-only record linking to the original dataset. Open original dataset below.
Health conditions among children under age 18, by selected characteristics: United States

NOTE: On October 19, 2021, estimates for 2016–2018 by health insurance status were revised to correct errors. Changes are highlighted and tagged at https://www.cdc.gov/nchs/data/hus/2019/012-508.pdf

Data on health conditions among children under age 18, by selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time.

SOURCE: NCHS, National Health Interview Survey, Family Core and Sample Child questionnaires.  For more information on the National Health Interview Survey, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.
New Jersey: 2011-2012 NSDUH

This report presents New Jersey\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Patent AT-E400549-T1: [Translated] METHOD FOR INHIBITING POLYMERIZATION DURING RECOVERY AND PURIFICATION OF UNSATURATED MONONITRILS

Economical processes are disclosed for recovery and refining of valuable nitrogen-containing organic compounds formed by catalytic oxidation of least one feed compound selected from the group consisting of propane, propylene, isobutane and isobutylene in the presence of ammonia to produce a gaseous. Processes of the invention include quenching the gaseous reactor effluent with an aqueous quench liquid; forming an aqueous solution comprising the corresponding unsaturated mononitrile, hydrogen cyanide and other organic co-products; and using an integrated sequence of distillations and phase separations to recover for recycle of a useful aqueous liquid, and obtain the desired nitrogen-containing products. According to the invention aqueous solutions are fractionated in an integrated system of multi-stage columns while an effective polymerization inhibiting amount of at least one member of a preselected class of p-phenylenediamine compounds is maintained therein.
The significance of opthalmologic evaluation in the early diagnosis of inborn errors of metabolism: the Cretan experience

Background
          The Inborn Errors of Metabolism (IEM) are far from the rare systemic diseases that mainly affect the neural tissue. There are very few written reports on ocular findings in subjects with IEM, thus it was interesting to study the frequency of ocular findings in the studied population and explore their contribution to the early diagnosis of IEM.
        
        
          Methods
          Our study involved the evaluation of IEM suspected cases, which had been identified in a rural population in Crete, Greece. Over a period of 3 years, 125 patients, who fulfilled the inclusion criteria of this study, were examined. Analytical physical examination, detailed laboratory investigation as well as a thorough ocular examination were made.
        
        
          Results
          A diagnosis of IEM was established in 23 of the 125 patients (18.4%). Ten (43.5%) of the diagnosed IEM had ocular findings, while 8 of them (34.8%) had findings which were specific for the diagnosed diseases. One patient diagnosed with glycogenosis type 1b presented a rare finding. Of the 102 non-diagnosed patients, 53 (51.96 %) presented various ophthalmic findings, some of which could be related to a metabolic disease and therefore may be very helpful in the future.
        
        
          Conclusions
          The ocular investigation can be extremely useful for raising the suspicion and the establishment of an early diagnosis of IEM. It could also add new findings related to these diseases. The early management of the ocular symptoms can improve the quality of life to these patients.
Elk Creek Seismic Waveforms 2010 (Part 7 of 7)

Coal bursts (damaging seismic events in underground coal mines) pose a substantial threat to operations and mine workers. The underground coal mines in Colorado’s North Fork Valley (NFV) have experienced many coal bursts, often with distinct characteristics from those of other US coal mining regions. To better understand these events and manage their associated risks, the National Institute for Occupational Safety and Health undertook a long-term monitoring campaign at the Elk Creek Mine in the NFV. The monitoring efforts included a seismic network composed of both surface and underground sensors, borehole pressure cells (BPCs), instrumented support Cans, convergence monitors, ground condition surveys, and several other data sources. This dataset consists of the event waveform files from the seismic network for the 983,379 events that were detected during the monitoring campaign. The waveforms are stored in HDF5 files that are broken up by week. Within the HDF5 files, the data are organized by station id, event time, and channel. The amplitudes are velocity in meters/second.
 
This is download 8 of 48 and corresponds to the time range between December 13, 2010, and January 3, 2011.
Mometasone furoate

Mometasone Furoate is a generic topical ointment containing 0.1% mometasone furoate, a corticosteroid used to treat skin inflammation like eczema or psoriasis. Manufactured by Sun Pharmaceutical Industries, Inc., under ANDA076624, it's available in 15g and 45g tubes but has been discontinued. This information was generated using AI and is provided for informational and research purposes only.
Duloxetine hydrochloride

Duloxetine Hydrochloride is a generic prescription drug that acts as a serotonin and norepinephrine reuptake inhibitor, commonly used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, and chronic pain. It comes in delayed-release capsules with strengths of 20 mg, 30 mg, and 60 mg, taken orally. Manufactured by Aurobindo Pharma Ltd. This information was generated using AI and is provided for informational and research purposes only.
AFCARS Report #28

This report provides preliminary estimates of Adoption and Foster Care Analysis and Reporting System (AFCARS) data for FY 2020. As states are permitted to resubmit AFCARS data, the estimates may change over time. This report reflects all AFCARS data received as of October 4, 2021 related to AFCARS reporting periods through September 30, 2020.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 525757: Heptyloxymethoxydimethylsilane

Chemical compound data from PubChem database. IUPAC Name: heptoxy-methoxy-dimethylsilane. Molecular Formula: C10H24O2Si. Molecular Weight: 204.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NSDUH 2024 Field Interviewer Manual

This detailed manual was used as a training guide for the Field Interviewers (FIs) who conducted the in-person 2023 National Survey on Drug Use and Health (NSDUH). It covers the information presented at the intensive training for new FIs. Although it is written for NSDUH FIs, researchers may find it helpful for learning about data collection challenges that could affect data quality. It also may be helpful for those designing their own field operations.The manual includes:An introduction to the survey;A guide to what is expected of FIs;FI instructions for locating sample dwelling units, contacting residents, obtaining participation, conducting the screening and interview, documenting their experiences;Quality control and administrative procedures for FIs; andCopies of materials that were mailed or given to respondents.
Patent AT-E40055-T1: [Translated] METHOD OF REACTIVATING CATALYSTS.

A method for reactivating catalysts which comprises the steps of:jetting dry steam into a reactor which is charged with the catalysts deteriorated in performance, in order to remove dust adhering to and accumulating on the surfaces of the catalysts;spraying wet steam of 0.4 or less in wetness thereinto to elute and remove water-soluble poisonous materials accumulated inside the catalysts; anddrying the catalysts with the dry steam.
Patent AT-E285412-T1: [Translated] THIENOPYRIMIDINE AS A PHOSPHODIESTERASE INHIBITOR

Chemical patent from PubChem database. Patent Number: AT-E285412-T1. Title: Novel Chemical Entity. Filing Date: 2012-10-22. Inventors: Yamamoto, Hiroshi, Schmidt, Hans. Abstract: The invention relates to a novel chemical entity with unique structural features and biological properties, suitable for development as a therapeutic ... IPC Classifications: C08G, C08K, A61K. This patent covers 28 claims related to 2 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Patent AT-E400500-T1: [Translated] METHOD AND DEVICE FOR MOVING A WELDING JAW

The method for controlling the transverse welding jaws (1, 6) of a vertical plastic bag making machine comprises moving each of them in an oval path (4) which brings them into contact with the tubular film over a vertical section (5) of the path to weld it. The speed of the jaws is adjusted so that the welding time is 0.1 - 0.8% of the total cycle time for the jaws : An independent claim is included for bag making machines operated using the method.
Patent AT-E399657-T1: [Translated] PRESSURE SENSOR FOR ROTATING PARTS AND METHOD FOR PRESSURE DETECTION THEREOF

Described herein is a magnetic pressure sensing device for rotatably moving parts, of the type comprising at least one magnetic field source element (13) associated to said rotatably moving part (11) and a magnetic field sensing element (14) associated to a fixed part (15) to measure parameters of a magnetic field (H) determined by said magnetic field source element (13), said parameters of the magnetic field (H) being a function of the pressure (P) applied to said rotatably moving part (11). The magnetic field source element (13) comprises means (22; 32; 53) for rotating around at least one axis (25; 45; 65) the direction of said magnetic field (H) as a function of the pressure (P) applied to said rotatably moving part (11). <IMAGE>
Compound 530147: 2-Methoxyphenylpropionic acid, trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3-(2-methoxyphenyl)propanoate. Molecular Formula: C13H20O3Si. Molecular Weight: 252.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
AFCARS Office Hours August - October 2022

The Children's Bureau Data Analytics and Reporting Team held three AFCARS Open Office Hours for the implementation of AFCARS 2020 in August, September, and October of 2022. These sessions were for state and tribal program administrators, child welfare data leaders, and information system programmers. It was an opportunity to ask questions specific to an agency's implementation. Below is one slide deck that combines the question and answers that were presented during the three sessions.

Metadata-only record linking to the original dataset. Open original dataset below.
Apraclonidine

Apraclonidine is an ophthalmic solution (eye drops) used to lower intraocular pressure in the eye. It works as an alpha-adrenergic agonist and is prescribed for conditions like glaucoma or before/after eye surgery. Available as a generic under brand names like Iopidine, it's manufactured by Sandoz Inc. and comes in 5 mL or 10 mL bottles. This information was generated using AI and is provided for informational and research purposes only.
Compound 527536: 1H-Perfluorononane

Chemical compound data from PubChem database. IUPAC Name: 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-nonadecafluorononane. Molecular Formula: C9HF19. Molecular Weight: 470.07. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401433-T1: [Translated] METHOD FOR PRODUCING 2-ALKINE-1-ACETALS

Preparation of 2-alkyne-1-acetal compounds (I) comprises electro-chemically oxidizing alcohol compounds (II) in the presence of 1-6C alkyl alcohol (A) or substance. Preparation of 2-alkyne-1-acetal compounds of formula (I) comprises electro-chemically oxidizing alcohol compounds (II) of formula (R 1>-C?=C-CH 2-OH) in the presence of 1-6C alkyl alcohol (A) or substance. R 1>1-20C alkyl, 2-20C alkenyl, 2-20C alkenyl, 3-12C cycloalkyl, 4-20C cycloalkyl-alkyl, 4-10C aryl (all optionally substituted with hydroxy, halo, 1-6C alkoxy, (1-6C alkoxy)-carbonyl, carboxyl or nitrile) or H; and R 2>, R 3>1-6C alkyl or a group of formula (R 1>-C?=C-CH 2-). [Image].
Patent AT-E400557-T1: [Translated] METHOD FOR PRODUCING ISONICOTINIC ACID DERIVATIVES

The present invention relates to a process for the manufacture of compounds of formula Ia or Ib and pharmaceutically acceptable additional salts thereof, wherein R is lower alkyl. The compounds of formula Ia or Ib are valuable intermediate products for the manufacture of compounds that are pharmaceutically active as adenosine A2a receptor antagonist or metabotropic Glutamate receptor 2 antagonist. Such compounds are important in the regulation of many aspects of cellular metabolism and in the modulation of different central nervous system activities.
2014 CMHS Uniform Reporting System (URS) Table for South Carolina

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for South Carolina. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Nebraska 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.